Back to top
more

The Cooper Companies (COO)

(Delayed Data from NSDQ)

$92.69 USD

92.69
776,707

+0.08 (0.09%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $93.10 +0.41 (0.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (203 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.

Indrajit Bandyopadhyay headshot

5 Stocks to Buy From the Prospering Dental Supplies Industry

by Indrajit Bandyopadhyay

Here we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, ALGN, COO, XRAY and PDCO.

Is the Options Market Predicting a Spike in The Cooper Companies (COO) Stock?

by Zacks Equity Research

Investors need to pay close attention to The Cooper Companies (COO) stock based on the movements in the options market lately.

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Reasons to Retain The Cooper Companies (COO) in Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

XRAY vs. COO: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Down -7.64% in 4 Weeks, Here's Why The Cooper Companies (COO) Looks Ripe for a Turnaround

by Zacks Equity Research

The Cooper Companies (COO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Cooper Companies (COO) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.

The Cooper Companies (COO) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for The Cooper Companies (COO) give a sense of how its business performed in the quarter ended April 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The Cooper Companies (COO) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of 2.33% and 1.75%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Bilibili (BILI) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Bilibili's (BILI) first-quarter 2023 performance will likely reflect strength in advertising revenues. However, increasing G&A and R&D expenses are expected to have kept margins under pressure.

Is a Surprise Coming for CooperCompanies (COO) This Earnings Season?

by Zacks Equity Research

CooperCompanies (COO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Beat Likely for Cooper Companies (COO) in Q2 Earnings?

by Zacks Equity Research

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.

What Makes The Cooper Companies (COO) a New Buy Stock

by Zacks Equity Research

The Cooper Companies (COO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so far this year.

XRAY vs. COO: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Why You Should Buy The Cooper Companies (COO) Stock Now

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -51.92% and 65.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of -2.42% and 1.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

XRAY vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Cardinal Health (CAH) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 17.57% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights West Pharmaceutical Services, The Cooper Companies and Henry Schein

by Zacks Equity Research

West Pharmaceutical Services, The Cooper Companies and Henry Schein have been highlighted in this Industry Outlook article.

3 Dental Supplies Stocks to Buy as Industry Prospects Recover

by Zacks Equity Research

Here, we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, COO and HSIC.

Here's Why You Should Retain NextGen (NXGN) Stock for Now

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.